# TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors

> **NCT07713732** · PHASE1 · RECRUITING · sponsor: **Treeline Biosciences, Inc.** · enrollment: 120 (estimated)

## Conditions studied

- Small Cell Lung Cancer ( SCLC )
- Neuroendocrine Cancer
- Malignant Pleural Mesotheliomas (Mpm)
- Synovial Sarcomas

## Interventions

- **DRUG:** TLN-499
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT07713732
- **Lead sponsor:** Treeline Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-05
- **Primary completion:** 2030-08-29
- **Final completion:** 2030-08-29
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07713732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07713732, "TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07713732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*